Key Findings
At the 2026 European Congress of Rheumatology (EULAR) Annual Meeting, Fate Therapeutics presented crucial data from its iPSC-derived, off-the-shelf CAR T-cell programs, FT819 and FT839, targeting autoimmune diseases and hematologic malignancies. Notably, Phase 1 clinical trial data for FT819 in systemic lupus erythematosus (SLE) patients demonstrated rapid and sustained clinical improvement when combined with low-intensity conditioning chemotherapy, while maintaining a favorable tolerability profile. For FT839, preclinical activities supporting an Investigational New Drug (IND) application are scheduled to conclude in 2026.
Technical and Clinical Details
FT819 is a universal donor iPSC-derived CD19-targeting CAR T-cell therapy designed to efficiently eliminate pathogenic autoreactive B cells in the treatment of autoimmune diseases. Data from SLE patients indicated a rapid reduction in disease activity immediately following treatment, suggesting the potential for long-lasting effects. This therapy holds promise as a new option for patients who are refractory to conventional immunosuppressive treatments. FT839, on the other hand, is a highly engineered iPSC-derived CAR T-cell expressing CARs against multiple target antigens, further incorporating immune evasion and apoptosis-inducing functionalities. Its development aims to address diverse unmet needs in both autoimmune diseases and hematologic malignancies.
Background and Industry Context
Autoimmune diseases such as Systemic Lupus Erythematosus (SLE) are challenging to achieve complete remission with conventional therapies, and long-term use of immunosuppressants carries significant side effects. While CAR T-cell therapy initially showed revolutionary success in hematologic cancers, its application to autoimmune diseases has rapidly advanced in recent years. Fate Therapeutics’ iPSC-derived, off-the-shelf CAR T cells offer advantages such as reduced manufacturing costs, rapid availability, and manufacturing consistency by eliminating the need for patient-specific cell collection and production. This represents a significant advancement in the field, with the potential to provide accessible treatments to a broader patient population.
Future Outlook
The positive clinical results of FT819 in SLE patients strongly support the future potential of iPSC-derived CAR T-cell therapy for autoimmune diseases. Fate Therapeutics plans to accelerate the clinical development of FT819, with plans to initiate a Phase 2 RECLAIM-LN study for lupus nephritis. Coupled with the progress towards an IND application for FT839, these programs demonstrate the company’s commitment to establishing leadership in iPSC-derived cell therapy and providing groundbreaking treatments for patients with refractory autoimmune diseases and cancer. The EULAR presentation is crucial for establishing the necessary credibility for these therapies to reach clinical practice.
Comments